Accelerated vs regular approval pathways: Differences in study characteristics in the approval of lung cancer treatments by the FDA from 2006 to 2018

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPRIBEIRO, TatianeBUSS, LewisALI, SanniNOBRE, Moacyr2021-01-252021-01-252020PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, v.29, suppl.3, Special Issue, p.641-642, 20201053-8569https://observatorio.fm.usp.br/handle/OPI/38972engrestrictedAccessAccelerated vs regular approval pathways: Differences in study characteristics in the approval of lung cancer treatments by the FDA from 2006 to 2018conferenceObjectCopyright WILEYPublic, Environmental & Occupational HealthPharmacology & Pharmacy1099-1557